Marroquin-Mucino M, Benito-Lopez J, Perez-Medina M, Aguilar-Cazares D, Galicia-Velasco M, Chavez-Dominguez R
Int J Mol Sci. 2024; 25(22).
PMID: 39596207
PMC: 11595078.
DOI: 10.3390/ijms252212141.
Jo Y, Sim H, Yun B, Park Y, Jin H
Exp Mol Med. 2024; 56(10):2113-2126.
PMID: 39349829
PMC: 11541569.
DOI: 10.1038/s12276-024-01317-9.
Paolini R, Molfetta R
Cancers (Basel). 2023; 15(18).
PMID: 37760586
PMC: 10527063.
DOI: 10.3390/cancers15184616.
Park J, Gazzaniga F, Kasper D, Sharpe A
Exp Mol Med. 2023; 55(9):1913-1921.
PMID: 37696895
PMC: 10545783.
DOI: 10.1038/s12276-023-01075-0.
Paolini R, Molfetta R
Int J Mol Sci. 2023; 24(16).
PMID: 37629138
PMC: 10455395.
DOI: 10.3390/ijms241612958.
DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D
Front Immunol. 2023; 14:1197053.
PMID: 37359555
PMC: 10285446.
DOI: 10.3389/fimmu.2023.1197053.
Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis.
Ohtsuki S, Wang C, Watanabe R, Zhang H, Akiyama M, Bois M
Cell Rep Med. 2023; 4(4):101012.
PMID: 37075705
PMC: 10140609.
DOI: 10.1016/j.xcrm.2023.101012.
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno.
Brazel D, Ou S, Nagasaka M
Lung Cancer (Auckl). 2023; 14:1-9.
PMID: 36636263
PMC: 9831070.
DOI: 10.2147/LCTT.S379389.
DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease.
Jacobs M, Pouw J, Olde Nordkamp M, Radstake T, Leijten E, Boes M
Immunother Adv. 2022; 1(1):ltaa004.
PMID: 36284900
PMC: 9585685.
DOI: 10.1093/immadv/ltaa004.
Update in TIGIT Immune-Checkpoint Role in Cancer.
Annese T, Tamma R, Ribatti D
Front Oncol. 2022; 12:871085.
PMID: 35656508
PMC: 9152184.
DOI: 10.3389/fonc.2022.871085.
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints.
Xu Y, He L, Fu Q, Hu J
Front Oncol. 2021; 11:759015.
PMID: 34858835
PMC: 8632143.
DOI: 10.3389/fonc.2021.759015.
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E
J Immunother Cancer. 2021; 9(11).
PMID: 34795004
PMC: 8603290.
DOI: 10.1136/jitc-2021-003134.
Acetate decreases PVR/CD155 expression via PI3K/AKT pathway in cancer cells.
Tran N, Lee I, Choi J, Kim S, Oh S
BMB Rep. 2021; 54(8):431-436.
PMID: 34353426
PMC: 8411046.
Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications.
Moon J, Oh Y, Ha S
BMB Rep. 2021; 54(8):403-412.
PMID: 34078531
PMC: 8411045.
CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus.
Zhao K, Ma L, Feng L, Huang Z, Meng X, Yu J
Front Mol Biosci. 2021; 7:608404.
PMID: 33490104
PMC: 7817973.
DOI: 10.3389/fmolb.2020.608404.
Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
Wang R, Li Y, Zhou Q, Lv S, Yuan K, Wu J
World J Clin Cases. 2020; 8(23):5935-5943.
PMID: 33344592
PMC: 7723709.
DOI: 10.12998/wjcc.v8.i23.5935.
TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C, Wang Y, Xun X, Wang S, Xiang X, Hu S
J Immunother. 2020; 43(8):236-243.
PMID: 32804915
PMC: 7566309.
DOI: 10.1097/CJI.0000000000000330.
Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.
Li Y, Zhou Q, Song Q, Wang R, Lyu S, Guan X
J Immunol Res. 2020; 2020:3948928.
PMID: 32411795
PMC: 7201814.
DOI: 10.1155/2020/3948928.
Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions.
Arruga F, Baffour Gyau B, Iannello A, Vitale N, Vaisitti T, Deaglio S
Int J Mol Sci. 2020; 21(5).
PMID: 32155826
PMC: 7084946.
DOI: 10.3390/ijms21051825.
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Xu Y, Cui G, Jiang Z, Li N, Zhang X
Oncol Lett. 2019; 17(3):2960-2968.
PMID: 30854074
PMC: 6365950.
DOI: 10.3892/ol.2019.9910.